NervGen Pharma Corp.
NGEN.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.31M | -18.45M | -17.44M | -17.62M | -16.99M |
| Total Depreciation and Amortization | 41.80K | 42.70K | 61.40K | 78.50K | 95.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.93M | 4.93M | 4.48M | 5.30M | 7.41M |
| Change in Net Operating Assets | 989.20K | 719.40K | 601.40K | 286.20K | 693.40K |
| Cash from Operations | -12.35M | -12.76M | -12.30M | -11.95M | -8.80M |
| Capital Expenditure | -- | -- | -- | 0.00 | -2.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.30K | 60.20K | 42.60K | 24.60K | -95.10K |
| Cash from Investing | 72.30K | 60.20K | 42.60K | 24.60K | -97.10K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.80K | -100.80K | -100.80K | -100.80K | -100.80K |
| Issuance of Common Stock | 7.31M | 2.55M | 24.43M | 24.19M | 23.99M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -604.80K | -487.60K | -1.63M | -1.63M | -1.63M |
| Cash from Financing | 4.74M | 1.39M | 16.82M | 16.66M | 16.51M |
| Foreign Exchange rate Adjustments | -284.50K | -118.30K | -217.50K | -4.40K | 211.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.82M | -11.43M | 4.35M | 4.72M | 7.83M |